The Aplastic Anaemia Trust appoints new CEO

The Board of Trustees are delighted to announce the appointment of Grazina Berry as the new CEO of the Aplastic Anaemia Trust, effective from 3 January 2018. As the CEO Grazina will lead the organisation’s growth and development with a primary focus on ensuring that people affected by aplastic anaemia and other rare bone marrow failures have access to the right treatment and support they so vitally need.

Sven Moos, Chairman of the Board of Trustees, said: “The Board and I are delighted to have Grazina as our new CEO. She will be instrumental in driving our strategy focused on helping AA patients, by funding research into defeating the disease as well as ensuring that patients and their families receive support in dealing with the illness by way of our Patient Support Group. Her vast experience and great energy will ensure that we reach the ambitious targets we have set for ourselves.”

Grazina brings with her extensive experience of patient-focused and innovative support provision, business strategy development, research and organisational excellence obtained in the not-for-profit and public sectors. Most recently, Grazina was the Group Director of Performance, Quality and Innovation at the Richmond Fellowship, a national mental health services provider, where she was instrumental in the organisation’s growth, improvement and journey towards greater user focus.

“I am very excited to be joining this unique organisation and working with our partners, patients, supporters and volunteers to ensure that everyone affected by aplastic anaemia and other rare bone marrow failures can lead healthy and fulfilling lives.”